Pathology Department, Instituto Valenciano de Oncología, Valencia, Spain; Patologika Laboratory Hospital Quiron-Salud, Valencia, Spain.
Department of Anatomical Pathology, Douglass Hanly Moir Pathology, Macquarie Park, Australia; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia; University of Sydney, Sydney, Australia.
Pathol Res Pract. 2022 Apr;232:153839. doi: 10.1016/j.prp.2022.153839. Epub 2022 Mar 11.
Our main goal was to investigate the potential utility of MDM2/CDK4 immunohistochemistry to act as surrogate for FISH to identify a subset of lipoma-like ALT/WDL that might, otherwise, be underdiagnosed on initial screening. Lack of cytologic atypia in lipomatous tumors with negative expression for MDM2/CDK4 IHC does not fully exclude the possibility of underlying MDM2/CDK4 amplification. Present study identified that isolated CDK4/p16 positive expression, in the absence of MDM2 expression, may have potential utility during the initial screening of these tumors but the proportion of conventional lipomas, which may also exhibit low levels of CDK4/p16 expression remains uncertain.
我们的主要目标是研究 MDM2/CDK4 免疫组化作为 FISH 的替代物的潜在效用，以鉴定可能在初始筛查中被误诊的脂肪肉瘤样 ALT/WDL 的亚组。在 MDM2/CDK4 IHC 表达阴性的脂肪性肿瘤中缺乏细胞学异型性并不能完全排除潜在的 MDM2/CDK4 扩增的可能性。本研究表明，在这些肿瘤的初始筛选中，CDK4/p16 表达阳性而 MDM2 表达缺失可能具有潜在的效用，但可能也表现出 CDK4/p16 低水平表达的传统脂肪瘤的比例仍不确定。
